Pharmaceutically active morpholinol

Details Pharmaceutically active morpholinol Pharmaceutically active morpholinol

2006-02-14

2006-02-14

Jones, Dwayne (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S238200, C544S170000, C544S173000

Reexamination Certificate

active

06998400

ABSTRACT:
Disclosed is the compound (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions comprising them, and processes for their preparation; also disclosed is a method of treating depression, attention deficit hyperactivity disorder (ADHD), obesity, migraine, pain, sexual dysfunction, Parkinson's disease, Alzheimer's disease, addiction to cocaine or tobacco products, seasonal affective disorder, chronic fatigue, narcolepsy or cognitive impairment using such compound, salts, solvates or compositions.

REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3622675 (1971-11-01), Koppe et al.
patent: 3630200 (1971-12-01), Higuchi
patent: 3819706 (1974-06-01), Mehta
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3885046 (1975-05-01), Mehta
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3960927 (1976-06-01), Metcalf et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4347176 (1982-08-01), Mehta
patent: 4347177 (1982-08-01), Phillips
patent: 4347178 (1982-08-01), Findlay et al.
patent: 4347257 (1982-08-01), Stern
patent: 4347382 (1982-08-01), Scharver
patent: 4355179 (1982-10-01), Findlay et al.
patent: 4356165 (1982-10-01), Findlay et al.
patent: 4393078 (1983-07-01), Peck
patent: 4425363 (1984-01-01), Stern
patent: 4435449 (1984-03-01), Stern
patent: 4438138 (1984-03-01), Stern
patent: 4507323 (1985-03-01), Stern
patent: 4571395 (1986-02-01), Peck
patent: 4656026 (1987-04-01), Coffman et al.
patent: 4687660 (1987-08-01), Baker et al.
patent: 4769027 (1988-09-01), Baker et al.
patent: 4798826 (1989-01-01), Peck
patent: 4835147 (1989-05-01), Roberts
patent: 4868344 (1989-09-01), Brown
patent: 4895845 (1990-01-01), Seed
patent: 4935429 (1990-06-01), Dackis et al.
patent: 4935439 (1990-06-01), Kashman et al.
patent: RE33994 (1992-07-01), Baker et al.
patent: 5217987 (1993-06-01), Berger
patent: 5358970 (1994-10-01), Ruff et al.
patent: 5399765 (1995-03-01), Gao et al.
patent: 5427798 (1995-06-01), Ludwig et al.
patent: 5447948 (1995-09-01), Seibly
patent: 5512593 (1996-04-01), Dante
patent: 5541231 (1996-07-01), Ruff et al.
patent: 5648347 (1997-07-01), Mehta et al.
patent: 5731000 (1998-03-01), Ruff et al.
patent: 5753712 (1998-05-01), Pinsker
patent: 5763493 (1998-06-01), Ruff et al.
patent: 6274579 (2001-08-01), Morgan et al.
patent: 6337328 (2002-01-01), Fang et al.
patent: 6342496 (2002-01-01), Jerussi et al.
patent: 6391875 (2002-05-01), Morgan et al.
patent: 2002/0052340 (2002-05-01), Jerussi et al.
patent: 2002/0052341 (2002-05-01), Fang et al.
patent: 977777 (1975-11-01), None
patent: 977778 (1975-11-01), None
patent: 0 118 036 (1984-09-01), None
patent: 0 170 430 (1986-02-01), None
patent: 0 171 227 (1986-02-01), None
patent: 0 467 488 (1992-01-01), None
patent: 63-91352 (1988-04-01), None
patent: 91/11184 (1991-08-01), None
patent: 92/18489 (1992-10-01), None
patent: 92/19226 (1992-11-01), None
patent: 93/21917 (1993-11-01), None
patent: 94/04138 (1994-03-01), None
patent: 94/20100 (1994-09-01), None
patent: 95/03791 (1995-02-01), None
patent: 95/22324 (1995-08-01), None
patent: 96/39133 (1996-12-01), None
patent: 97/29735 (1997-08-01), None
patent: 98/50044 (1998-11-01), None
patent: 99/37305 (1999-07-01), None
patent: 01/62257 (2001-08-01), None
Cooper et al., “Behavioral and Biochemical Effects of the Antidepressant, Bupropion (Wellbutrin): Evidence for Selective Blockade of Dopamine Uptake in Vivo,”The Journal of Pharmacology and Experimental Therapeutics, 1980, vol. 215, No. 1.
Ferris et al., “Some Neurochemical Properties of a New Antidepressant, Bupropion Hydrochloride (Wellbutrin),”Drug Development Research, 1981, vol. 1, pp. 21-35.
Maxwell, et al., “Bupropion,”Pharmacol&Biochem Properties Drug Substances(M E Goldberg, Ed),Am Pharm Assoc. Pub., Washington, 1981, vol. 3, pp. 1-55.
Findlay, et al., “Pharmacokinetics of Bupropion, a Novel Antidepressant Agent, Following Oral Administration to Healthy Subjects,”European Journal of Clinical Pharmacology, 1981, vol. 21, pp. 127-135.
Butz, et al., “Radioimmunoassay and Pharmacokinetic Profile of Bupropion in the Dog,”The Journal of Pharmacology and Experimental Therapeutics, 1981, vol. 217, No. 3.
Ferris et al., “Bupropion: A New Antidepressant Drug, The Mechanism of Action of Which is Not associated with Down-Regulation of Postsynaptic β-Adrenergic, Serotonergic (5-HT2), α2-Adrenergic, Imipramine and Dopaminergic Receptors in Brain,”Neuropharmacology, 1983, vol. 22, No. 11, pp. 1257-1267.
Mehta, “The Chemistry of Bupropion,”J. Clinical Psychiatry, May 1983, 44:5 (Sec. 2).
Schroeder, David, “Metabolism and Kinetics of Bupropion,”J. Clinical Psychiatry, May 1983, 44:5 (Sec. 2).
Lai, et al., “Clinical Pharmacokinetics of Bupropion: A Review,”J. Clinical Psychiatry, May 1983, 44:5 (Sec. 2).
Cooper et al., “Determination of Bupropion nd Its Major Basic Metabolites in Plasma by Liquid Chromatography with Dual-Wavelength Ultraviolet Detection,”Journal of Pharmaceutical Sciences, Aug. 1984, vol. 73, No. 8.
Laizure et al., “Stability of Bupropion and its Major Metabolites in Human Plasma,”Therapeuytic Drug Monitoring, 1985, vol. 7, pp. 447-450.
Cooper, et al., “Bupropion: Possible Rose of Major Metabolites in Mode of Action,”Clin. Pharmacol. Ther., Feb. 1985, vol. 37, No. 2.
DeVane, et al., “The Effect of Experimentally-Induced Renal Failure on Accumulation of Bupropion and its major basic metabolites in plasma and brian of guinea pigs,”Psychopharmacology, 1986, vol. 89, pp. 404-408.
Perumal, et al., “Effect of Plasma from Patients Contianing Bupropion and its Metabolites on the Uptake of Norepinephrine,”Neuropharmacology, 1986, vol. 25, No. 22, pp. 199-202.
Thomas Smith et al., “Brain regional [3H]flunitrazepam binding in rats chronically treated with bupropion or B.W.306U,”Brain Research, 1986, 367, pp. 385-389.
Ferris et al., “Mechanism of Antidepressant Activity of Bupropion,”J Clin Psychiatry Monograph, 1993, vol. 11, pp. 2-14.
Musso, et al., Synthesis and Evaluation of the Antidepressant Activity of the Enantiomers of Bupropion,Chirality, 1993, vol. 5, pp. 495-500.
Hsyu, et al., “Pharmacokinetics of Bupropion and its Metabolites in Cigarette Smokers versus Nonsmokers,”J. Clin. Pharmacol., 1997, vol. 37, pp. 737-743.
Modell, et al., “Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline,”Clinical Pharmacology&Therapeutics, 1996, vol. 61, No. 4.
Cooper, et al., “Evidence that the Acute Behavioral and Electrophysiolgical Effects of Bupropion (Wellbutrin) are Mediated by a Noradrenergic Mechanism,”Neuropsychopharmacology, 1994, vol. 11, No. 2, 99133-141.
Bannon et al., 1998, “Broad-spectrum, non-opoid analgesic activity by selective modulation of neuronal nicotinic acetylchroline receptors,”Science, vol. 279, pp. 77-81.
Bischoff et al., 1984, “Affinity changes of rat striatal dopamine receptor in vivo after acute bupropion treatment,”Eur. J. Pharmaco., vol. 104, pp. 173-176.
Blondel-Hill et al., 1993, “Treatment of the chronic fatigue syndrome,”Drugs, vol. 46, No. 4, pp. 639-651.
Borowski, T.B., et al., 1993, Amphetamine and antidepressant drug effects of GABA—and NMDA—related seizures,Brain Res. Bull., vol. 30, pp. 607-610.
Calabrese, J.R. et al., 1991, “Treatment of depression,”Primary Care, vol. 18, No. 2, pp. 421-433.
Castaldi, G. et al., 1987, “Tataric acid and efficient chiral auxillary: new asymmetric synthesis of 2-alkyl-2-arylacetic acids,”J. Org. Chem., vol. 52, p. 3018.
Castello, R.A., and Mattons, A.M.,J. Pharm. Sci., vol. 51, No. 2, pp. 106-108 (1962).
Charney, D.S. et al., 1983, “Monoamine receptor sensitivity and depression: clinical studies of antidepressant

Affiliated with

Also associated with

Rating

Pharmaceutically active morpholinol does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutically active morpholinol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically active morpholinol will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3673355